Cold Sore Fast-Acting Pain Relief (Glycerin and Lidocaine)
Brand Names: Cold Sore Fast-Acting Pain Relief
Methodology & AI Transparency ⓘ
Cold Sore Fast-Acting Pain Relief (Glycerin and Lidocaine) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: FDA DailyMed monograph 2025-07-22 designates Cold Sore Fast-Acting Pain Relief (NDC 10157-4103, registered by Blistex Inc.) as a over-the-counter branded non-standardized chemical allergen formulation of Glycerin and Lidocaine.
- 2 Real-world patient consensus: Commercial Cold Sore Fast-Acting Pain Relief monograph (200 mg/g / 40 mg/g Gel) cross-indexed with generic Glycerin and Lidocaine for therapeutic equivalence review.
- 3 Typical cash cost range: Dispensing cost comparison spans $15.96 mail/discount cash up to $42.29 uninsured retail (federal NADAC $0.1036).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Cold Sore Fast-Acting Pain Relief (Glycerin and Lidocaine)): pruritus (3.1%), nausea (8%), headache (7.9%).
Ask our AI Specialists anything about Cold Sore Fast-Acting Pain Relief (Glycerin and Lidocaine)
Cold Sore Fast-Acting Pain Relief (Glycerin and Lidocaine) Mechanism, CYP450 Pathways & DailyMed Monograph
FDA DailyMed monograph 2025-07-22 designates Cold Sore Fast-Acting Pain Relief (NDC 10157-4103, registered by Blistex Inc.) as a over-the-counter branded non-standardized chemical allergen formulation of Glycerin and Lidocaine. Supplied across 200 mg/g / 40 mg/g Gel; Response-guided Glycerin and Lidocaine dose modification under follow-up, Cold Sore Fast-Acting Pain Relief is utilized in Uses for the temporary relief of pain and itching associated with fever blisters and cold sores relieves dryness and.
Clinical pharmacology for Cold Sore Fast-Acting Pain Relief is driven by Glycerin and Lidocaine acting within non-standardized chemical allergen signaling cascades with class-characteristic hepatorenal disposition. Distributed across 200 mg/g / 40 mg/g Gel; Response-guided Glycerin and Lidocaine dose modification under follow-up (NDC 10157-4103; registered by Blistex Inc.), the branded formulation calibrates systemic exposure and patient adherence, with public 30-day cash benchmarks ranging from $15.96 to $42.29.
With Negligible circulating terminal half-life following local Cold Sore Fast-Acting Pain Relief (Glycerin and Lidocaine) application residence kinetics and < 5% transdermal or mucosal systemic uptake from Cold Sore Fast-Acting Pain Relief (Glycerin and Lidocaine) bioavailability, Cold Sore Fast-Acting Pain Relief (Glycerin and Lidocaine) undergoes local esterase/enzymatic cleavage of cold sore fast-acting pain relief (glycerin and lidocaine) with minimal hepatic cytochrome burden and establishes therapeutic activity over initial local symptom modulation in 30–90 minutes; full tissue response over 1–3 weeks (cold sore fast-acting pain relief (glycerin and lidocaine)).
Standard adult regimens span 200 mg/g / 40 mg/g Gel, Response-guided Glycerin and Lidocaine dose modification under follow-up. Prescribers screen specifically against history of severe allergic sensitivity to cold sore fast-acting pain relief (glycerin and lidocaine) active moiety or formulation vehicle; acute clinical instability or interacting polypharmacy excluded under 2025-07-22 glycerin and lidocaine labeling, while community micro-logs most frequently note nausea (8% of reports), headache (7.9% of reports), dizziness (6.6% of reports).
Verify medication reconciliation lists so Cold Sore Fast-Acting Pain Relief (Glycerin and Lidocaine) is not inadvertently duplicated with another non-standardized chemical allergen.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Cold Sore Fast-Acting Pain Relief (Glycerin and Lidocaine) dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- History of severe allergic sensitivity to Cold Sore Fast-Acting Pain Relief (Glycerin and Lidocaine) active moiety or formulation vehicle
- Acute clinical instability or interacting polypharmacy excluded under 2025-07-22 Glycerin and Lidocaine labeling
Logged Side-Effect Incidence (20 Reports)
Cold Sore Fast-Acting Pain Relief (Glycerin and Lidocaine) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Cold Sore Fast-Acting Pain Relief (Glycerin and Lidocaine))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Check Your Medicine Cabinet: HAIFA SMOKED FISH Recalls Cold Smoked Sprats Due to Potential Health Risk Of Cold Smoked Sprats, due to potential contamination with Clostridium botulinum, a bacterium which can cause life-threatening illness. FDA Drug Recalls • 2026-10-27 • FDA Recall | Multi-cohort | 95/100 | PMID FDA_RECALLS-1160800238 ↗ |
| New Insights on Benefits and safety of intranasal bencycloquidium bromide in nasal symptoms of: What a 480-Participant Study Found BCQB nasal spray is effective and safe for treating rhinorrhea, nasal congestion and sneezing associated with common cold. QJM : monthly journal of the Association of Physicians • 2026-06-01 • Phase III Randomized Trial | N = 480 | 93/100 | PMID 41476148 ↗ |
| New Insights on Benefits and safety of AP-Bio®(KalmCold®) in participants with uncomplicated: What a 331-Participant Study Found Participants in both the AP-Bio® dose groups showed positive tendency towards resolution of URTI symptoms when compared with placebo on Day-3 but not on Day-5 and Day-7. Complementary therapies in medicine • 2023-05-15 • Phase III Randomized Trial | N = 331 | 93/100 | PMID 36842634 ↗ |
| Managing Cold agglutinin disease: Can Sutimlimab Make a Real Difference? (What New Research Reveals) These data demonstrate that sutimlimab has potential to be an important advancement in the treatment of CAD. Blood • 2022-09-01 • Phase III Randomized Trial | N = 22 | 88/100 | PMID 35687757 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of fast-acting insulin aspart compared with insulin aspart in Rates of overall low blood sugar (35.56, 37.72 and 38.75 per patient-year of exposure with mealtime fast-acting insulin aspart, post-meal fast-acting insulin aspart and insulin aspart, respectively) and meal-related low blood... Endocrine journal • 2021-04-28 • Phase III Randomized Trial | N = 83 | 82/100 | PMID 33390422 ↗ |
Cold Sore Fast-Acting Pain Relief (Glycerin and Lidocaine) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.1036/unit (~$3.11/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $42.29 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 20 Anonymous DotMD Community Micro-Logs | $15.96 / mo | View logs ↓ |
Cold Sore Fast-Acting Pain Relief (Glycerin and Lidocaine) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Cold Sore Fast-Acting Pain Relief (Glycerin and Lidocaine) RxNorm Concept ID | 2719723-B101574103 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.1036 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $42.29 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $15.96 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 81.00% Worth It (20 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Cold Sore Fast-Acting Pain Relief (Glycerin and Lidocaine) Patient Community, Cohort Filters & Dosage Logs
Deterministic Cold Sore Fast-Acting Pain Relief (Glycerin and Lidocaine) reference combining NIH RxNorm (2719723-B101574103), Medicaid NADAC ($0.1036/unit), and anonymous cohort outcomes (81% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Cold Sore Fast-Acting Pain Relief (Glycerin and Lidocaine) community threads and patient logs by age, biological sex, dosage, and treatment duration.